P
Paul B. Fisher
Researcher at Virginia Commonwealth University
Publications - 486
Citations - 35304
Paul B. Fisher is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 80, co-authored 449 publications receiving 31149 citations. Previous affiliations of Paul B. Fisher include Discovery Institute & Columbia University Medical Center.
Papers
More filters
Journal ArticleDOI
Astrocyte Elevated Gene-1 (AEG-1) Contributes to Non-thyroidal Illness Syndrome (NTIS) Associated with Hepatocellular Carcinoma (HCC).
Jyoti Srivastava,Chadia L. Robertson,Rachel Gredler,Ayesha Siddiq,Devaraja Rajasekaran,Maaged A. Akiel,Luni Emdad,Valeria R. Mas,Nitai D. Mukhopadhyay,Paul B. Fisher,Devanand Sarkar +10 more
TL;DR: A novel role of AEG-1 is identified regulating cancer-associated NTIS in the context of hepatocellular carcinoma (HCC) and an inverse correlation was observed between AEG and DIO1 levels in human HCC patients.
Journal ArticleDOI
MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF.
Anjan K. Pradhan,Praveen Bhoopathi,Sarmistha Talukdar,Danielle Scheunemann,Devanand Sarkar,Webster K. Cavenee,Swadesh K. Das,Luni Emdad,Paul B. Fisher +8 more
TL;DR: This research uncovers a distinct role of mda-7/IL-24 in the regulation of miRNA biogenesis through alteration of the MITF-DICER pathway.
Journal ArticleDOI
Searching for a cure: gene therapy for glioblastoma.
Paul Dent,Adly Yacoub,Margaret A. Park,Devanand Sarkar,Khalid Shah,David T. Curiel,Steven Grant,Paul B. Fisher +7 more
TL;DR: This review will examine how gene therapeutic approaches have been used in the past and are continuing to be used alongside cell signaling modulators and DNA damaging agents as clinical tools to treat GBM.
Journal ArticleDOI
Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules
Michael Hedvat,Luni Emdad,Swadesh K. Das,Keetae Kim,Santanu Dasgupta,Shibu Thomas,Bin Hu,Shan Zhu,Rupesh Dash,Bridget A. Quinn,Regina A. Oyesanya,Timothy P. Kegelman,Upneet K. Sokhi,Siddik Sarkar,Eda Erdogan,Mitchell E. Menezes,Praveen Bhoopathi,Xiang-Yang Wang,Martin G. Pomper,Jun Wei,Bainan Wu,John L. Stebbins,Paul Diaz,John C. Reed,Maurizio Pellecchia,Devanand Sarkar,Paul B. Fisher,Paul B. Fisher +27 more
TL;DR: The isolation of Sabutoclax, an optically pure isomer of Apogossypol displaying superior efficacy and reduced toxicity is illustrated, illustrating the power of combining structure-based modeling with rational design to predict appropriate derivatives of lead compounds to be empirically tested and evaluated for bioactivity.
Book ChapterDOI
Can CpG methylation serve as surrogate markers for immune infiltration in cancer
TL;DR: Results from comparative pathways analyses offer further justification to methylation at certain CpG sites as being indicators of cancer immune infiltration, and possibly of predicting patient response to immunotherapeutic drugs.